Born and raised in Canada, Eric studied chemistry at the University of Amsterdam (M.Sc), obtained his Ph.D. degree (Biochemistry) in Biochemistry at Western University (London, Canada) after which he started his own research group specializing in RNA biology of healthy and diseased cells at the Department of Nephrology at the Leiden University Medical Center (LUMC).

In 2015, his research group pivoted to anti-viral RNA therapeutic strategies, primarily in the setting of organ/kidney transplantation, which was made possible by realizing several research grants that enabled early-stage drug development. In 2019, he left the LUMC and founded Hybridize Therapeutics to accelerate the drug development process and prepare for the transition of the technology to the clinic. In 2022, the drug was outlicensed and partnered with AiCuris Anti-Infectives GmbH (Wuppertal, Germany). Phase 1 clinical trials for AIC468 started in October 2024.